Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Expected BioCircuit revenue contributions were not included in Axogen’s most recently issued full-year 2026 revenue growth guidance.

Rhea-AI Summary

Axogen (AXGN) has completed its previously announced acquisition of BioCircuit Technologies, adding NerveTape to its peripheral nerve repair portfolio.

NerveTape is an FDA-cleared sutureless device for repairing transected, or severed, nerves. BioCircuit is a privately held medical device company that develops and commercializes devices for peripheral nerve repair and neuromodulation.

Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue. This contribution was not included in its most recently issued full-year 2026 guidance of at least 24% revenue growth. The company continues to expect gross margin of at least 73% and to be free cash positive for full-year 2026.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointCompleted BioCircuit acquisition adds the FDA-cleared NerveTape sutureless nerve repair device to Axogen’s portfolio.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Approximately $34 million in 2027 revenue contribution expected from BioCircuit.
• Minor point. Forward-looking: it has not happened yet and may not happen.Approximately $6 million in fourth-quarter 2026 revenue contribution expected from BioCircuit.
• Minor point. Forward-looking: it has not happened yet and may not happen.At least 24% revenue growth in most recently issued full-year 2026 guidance excludes BioCircuit’s contribution.
• Minor point. Forward-looking: it has not happened yet and may not happen.At least 73% gross margin remains Axogen’s expectation for full-year 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Free cash positive remains Axogen’s expectation for full-year 2026.

Negative

• None.

Key Figures

2026 revenue growth guidance: at least 24% Gross margin outlook: at least 73%

2026 revenue growth guidance

at least 24%

Previously issued full-year guidance; BioCircuit contribution was not included

Gross margin outlook

at least 73%

Full-year 2026 expectation

Historical Context

1 past event · Latest: Sep 10

1 event

1. Sep 10

   Acquisition agreement

   24h Move

   -11.5%

   Definitive $200 million cash agreement established terms for the acquisition later completed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

FDA-cleared, nitinol, neuromodulation, transected nerves

4 terms

FDA-cleared regulatory

"the first FDA-cleared sutureless device for repairing transected nerves"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

nitinol technical

"precision Nitinol design and manufacturing"

Nitinol is a nickel‑titanium metal alloy known for “shape memory” and spring‑like flexibility: it can return to a preset shape after bending or heating, like a paperclip that snaps back when warmed. Investors track it because those unique properties make it a go‑to material for medical implants, surgical tools and precision devices, so changes in availability, cost, regulation or technical advances can directly affect manufacturers’ product performance, margins and regulatory risk.

neuromodulation medical

"medical devices for peripheral nerve repair and neuromodulation"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

transected nerves medical

"device for repairing transected nerves"

Nerves that have been physically cut or severed, either partially or completely, so the normal electrical signals between the body and the brain or spinal cord are interrupted. This differs from nerve injury caused by pressure, inflammation, or disease: a transection is a mechanical break in the nerve fiber that typically prevents signal transmission until the nerve is surgically repaired or, in some peripheral nerves, regenerates over time under certain biological conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.

“This is a significant day for Axogen and the surgeons and patients we serve,” said Michael Dale, President and Chief Executive Officer of Axogen. “NerveTape represents a new standard of care as the first sutureless nerve repair option—one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons’ everyday need to repair nerves and aligns perfectly with Axogen’s mission to make the restoration of peripheral nerve function an expected standard of care. It is therefore an ideal fit with our direct sales organization and hospital contracting capabilities, enabling and unlocking NerveTape’s full potential.”

The Company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 and approximately $34 million to 2027 revenue. This contribution was not included in Axogen’s most recently issued full-year 2026 guidance of at least 24% revenue growth. The Company continues to expect gross margin to be at least 73% and to be free cash positive for the full-year 2026.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen’s product portfolio includes Avance^® (acellular nerve allograft-arwx), Avance^® Nerve Graft, Axoguard Nerve Connector^®, Axoguard Nerve Protector^®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap^®, and Avive+ Soft Tissue Matrix^®.​

About BioCircuit Technologies

BioCircuit Technologies, based in Atlanta, Georgia, develops and commercializes medical devices for peripheral nerve repair and neuromodulation, with expertise in biomaterials, precision Nitinol design and manufacturing, and bioelectronics for nerve stimulation and recording. Its first commercial product, NerveTape™, is the first FDA-cleared sutureless device for repairing transected nerves. BioCircuit has been supported by small business funding from the National Institutes of Health along with private investment from Alsora Capital, GRA Venture Fund, Michael Masters of Masters Capital Management, and other investors. For more information, visit www.biocircuit.com.

Cautionary Statements Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding Axogen’s ability to successfully integrate BioCircuit and realize the anticipated benefits of the acquisition, the expected financial impact of the acquisition and related financial guidance and outlook, including expected revenue, revenue growth, revenue contribution from BioCircuit in the fourth quarter of 2026 and in 2027, gross margin, free cash flow, as well as expectations regarding the commercialization and adoption of NerveTape and the expansion of Axogen’s addressable market. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties related to the integration of BioCircuit and the realization of the anticipated benefits of the acquisition and the risks and uncertainties inherent in Axogen’s business, including the risks and uncertainties described in the Company’s periodic filings with the SEC. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Axogen can be found under the heading “Risk Factors” in Axogen’s periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2025 and in its subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Axogen undertakes no obligation to update or revise any forward-looking statements contained herein.

Media Contact:

Axogen, Inc.
InvestorRelations@axogeninc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Axogen acquire in the BioCircuit Technologies deal?

Axogen completed its acquisition of BioCircuit Technologies, the developer of NerveTape. NerveTape is an FDA-cleared sutureless device for repairing severed peripheral nerves.

How much revenue does Axogen expect BioCircuit to contribute?

Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue. The contribution was not included in Axogen’s most recently issued full-year 2026 guidance of at least 24% revenue growth.